Related Experiment Video
Updated: Jan 17, 2026

14:03
High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
2.4K
MTF-hERG: A Multi-Type Features Fusion-Based Framework for Predicting hERG Cardiotoxicity of Compounds
IEEE Transactions on Computational Biology and Bioinformatics
|September 25, 2025
Summary
A new deep learning model, MTF-hERG, accurately predicts human ether-a-go-go-related gene (hERG) cardiac toxicity by fusing molecular features. This enhances drug development efficiency and safety by identifying potential hERG blockers early.
Area of Science:
- Computational chemistry and toxicology
- Pharmacology and drug discovery
- Artificial intelligence in medicine
Background:
- Human ether-a-go-go-related gene (hERG) channel inhibition causes life-threatening cardiac arrhythmias.
- Accurate prediction of hERG cardiac toxicity is crucial for safe drug development.
- Traditional toxicity assessments are time-consuming and have low throughput.
Purpose of the Study:
- To develop a novel deep learning framework, MTF-hERG, for accurate prediction of hERG cardiac toxicity.
- To enhance drug development efficiency and reduce risks associated with hERG channel blockers.
Main Methods:
- Proposed a multi-type feature fusion framework (MTF-hERG) integrating molecular fingerprints, 2D images, and 3D graphs.
- Employed fully connected neural networks, DenseNet, and Equivariant Graph Neural Networks for feature extraction.
- Utilized deep feature fusion and fully connected layers for classification and regression predictions of hERG activity.
Main Results:
- MTF-hERG achieved high average performance metrics: ACC (0.926), AUC (0.943), AUPR (0.913), RMSE (0.453), and R² (0.681).
- The model significantly outperformed existing state-of-the-art methods on benchmark datasets.
- Visualization revealed key predictive features and decision mechanisms, aiding molecular structure optimization.
Conclusions:
- The MTF-hERG framework demonstrates excellent predictive performance for hERG cardiac toxicity.
- This tool offers robust support for drug development, improving safety and efficiency.
- MTF-hERG has the potential to significantly impact drug discovery and personalized medicine.
Related Concept Videos
Cardiovascular Drugs: Classification based on Therapeutic Indications
4.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.0K
Combined Effects of Drugs: Synergism
6.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
6.8K
Mutagenicity and Carcinogenicity
1.9K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.9K

